Stock Analiz

Bioventus Inc. BVS

Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026

$10.66Market cap $730M
Open the interactive analysis →

Bioventus Inc. (BVS) is a healthcare company listed in the US with a market value of about $730M. In the twelve months to September 26, 2026 it had revenue of $586M and net income of $57M, a net margin of 9.8%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is value (3/5); the weakest is future growth (1/5).

Key numbers: a P/E of 13.3, a price to free cash flow of 8.6, 5-year revenue growth of 12% a year, a 5-year average ROIC of -4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 50% below the current price.

About Bioventus

Bioventus is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $340M in 2019 to $568M in 2025, growth of about 8.9% a year. It was profitable in 4 of the last 7 years in our data. Its share count rose by 12% over three years (dilution for shareholders). It spends 2% of revenue on research and development.

Score: 1.8 / 5

Value3/5
Future growth1/5
Track record1/5
Financial health3/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • Positive free cash flow
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)13.3
Forward P/E12.8
P/FCF8.6
P/S1.2
P/B3.0
EV/EBITDA9.3
PEG1.98
Dividend yield0.00%
FCF yield11.6%
Shareholder yield0.0%
Intrinsic value vs. price−50%

Growth and quality

Revenue growth (1 yr)-0.9%
Revenue growth (5 yrs, per year)12.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-11.9%
ROIC (5-yr avg.)-4.2%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$586M$568M$573M$512M$512M$431M$321M$340M
Net income$57M$23M-$36M-$156M-$159M$19M$16M$7M
Free cash flow$85M$72M$38M$8M-$15M$9M$55M$38M
EPS (diluted)$0.80$0.33$-0.56$-2.49$-2.59$-0.15——
Net margin9.8%4.0%-6.3%-30.5%-31.0%4.5%5.1%2.0%
ROIC—8.8%-2.8%-11.1%-16.8%1.1%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $16.60, 56% above the current price; targets range from $15.00 to $18.00; the consensus rating is “Strong buy”; expected EPS is $0.77 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Bioventus’s P/E ratio?

About 13.3, based on the last twelve months of diluted earnings per share (forward P/E about 12.8).

Is Bioventus stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 50% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Bioventus pay a dividend?

Not currently.

Is Bioventus a good stock to buy?

We do not give buy or sell advice. Bioventus scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.